CLAIMS

1. Use of an IL-33 axis binding antagonist in the manufacture of a medicament for treating or preventing acute respiratory distress syndrome (ARDS) in a patient, wherein an effective amount of the IL-33 axis binding antagonist is to be administered to the patient, wherein the patient has viral pneumonia.
2. The use of claim 1, wherein the medicament is capable of preventing ARDS in said patient.
3. The use of any preceding claim, wherein the patient has mild, moderate, or moderate-to-severe hypoxemia.
4. The use according to any preceding claim, wherein the patient has hypercarbia.
5. The use of any preceding claim, wherein the patient has excessive pulmonary inflammation.
6. The use according to any preceding claim, wherein the medicament is capable of reducing or inhibiting inflammation in the lung.
7. The use according to any preceding claim, wherein the patient has coronavirus 2 (SARS-CoV-2) infection.
8. The use according to claim 7, wherein the ARDS is induced by SARS-CoV-2.
9. The use according to any preceding claim, wherein the patient's partial pressure of oxygen is less than 79 mm HG.
10. The use according to any of claims 1 to 8, wherein the patient's partial pressure of oxygen is between 60 and 79 mm HG, inclusive.
11. The use according to any of claims 1 to 9, wherein the patient's partial pressure of oxygen is less than 60 mm HG.
12. The use according to any preceding claim, wherein the patient is not or has not yet received mechanical ventilation.
13. The use according to any preceding claim, wherein the IL-33 axis binding antagonist is an anti-IL-33 antagonist, an anti-ST2 antagonist or an IL1-RAcP antagonist.
14. The use of claim 13, wherein the antagonist is an antibody, or antigen binding fragment thereof.
15. The use of claim 14, wherein the antibody is an anti-IL-33 antibody, or antigen binding fragment thereof.
16. The use according to claim 15, wherein the anti-IL33 antibody, or antigen binding fragment thereof, comprising a VHCDR1 having the sequence of SEQ ID NO: 37, a VHCDR2 having the sequence of SEQ ID NO: 38, a VHCDR3 having the sequence of SEQ ID NO: 39, a

VLCDR1 having the sequence of SEQ ID NO: 40, a VLCDR2 having the sequence of SEQ ID NO: 41, and a VLCDR3 having the sequence of SEQ ID NO: 42.

17. Use of an anti-IL33 antibody, or antigen binding fragment thereof, comprising a VHCDR1 having the sequence of SEQ ID NO: 37, a VHCDR2 having the sequence of SEQ ID NO: 38, a VHCDR3 having the sequence of SEQ ID NO: 39, a VLCDR1 having the sequence of SEQ ID NO: 40, a VLCDR2 having the sequence of SEQ ID NO: 41, and a VLCDR3 having the sequence of SEQ ID NO: 42 in the manufacture of a medicament for preventing or treating acute respiratory distress syndrome (ARDS) induced by coronavirus 2 (SARS-CoV-2) infection in a patient, wherein an effective amount of the anti-IL33 antibody, or antigen binding fragment thereof is to be administered to the patient.